| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond...
KDP updated its financing package related to the acquisition, now including two new strategic investment agreements totaling $7...
Morgan Stanley analyst Michael Cyprys maintains KKR (NYSE:KKR) with a Overweight and lowers the price target from $170 to $166.
Seasoned team to lead new platform anchored by stable, long-term capitalGalaxy will generate asset-backed contractual cash flow...
- Reuters Exclusive
https://www.ft.com/content/a761ab0f-19e7-476c-a7b1-4a43a3d746f6